Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer.
Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of progression-free survival (PFS) for gefitinib (G)in patients treated with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) gefitinib compared with cisplatin plus docetaxel (CD) as first-line treatment of stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer (NSCLC). This report presents final overall survival (OS) data. Patients were randomized between G (250mg/day orally) and cisplatin (80mg/m2 intravenously) plus docetaxel (60mg/m2 intravenously), administered every 21 days for three to six cycles. After the exclusion of 5 patients, 172 patients (86 in each group, modified intention-to-treat population) were included in the survival analysis. OS was re-evaluated using updated data (data cutoff, 30 Sep. 2013; median follow-up time 59.1 months). The Kaplan-Meier method and the log-rank test were used for analysis, and hazard ratios (HRs) for death were calculated using the Cox proportional hazards model. OS events in the G group and CD group were 68 (79.1%) out of 86, and 59 (68.6%) out of 86, respectively. Median survival time for G and CD were 34.9 and 37.3 months, respectively, with a HR of 1.252 (95% confidence interval (CI): 0.883-1.775, P = 0.2070). Multivariate analysis identified postoperative recurrence and stage IIIB/IV disease as independent prognostic factors, with a HR of 0.459 (95% CI: 0.312-0.673, P < 0.001). Median survival time (postoperative recurrence versus stage IIIB/IV disease) were 44.5 and 27.5 months in G group and 45.5 and 32.8 months in CD group, respectively. G did not show OS benefits over CD as first-line treatment. OS of patients with postoperative recurrence was better than that of stage IIIB/IV disease, even though both groups had metastatic disease.This study was registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.